Amgen's Repatha Receives Positive CHMP Opinion for Cardiovascular Risk Reduction

Amgen has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for its drug Repatha, indicating its potential to reduce cardiovascular risk.